The pharmacologic profile of desloratadine: A review

Allergy: European Journal of Allergy and Clinical Immunology, Supplement

Volumn 56, Issue 65, 2001, Pages 7-13

  Henz, B M ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Allergic rhinitis; Antihistamine; Cardiac safety; Desloratadine; Pharmacodynamics; Pharmacokinetics; Urticaria

Indexed keywords

CYTOCHROME P450 INHIBITOR; DESLORATADINE; ERYTHROMYCIN; HISTAMINE H1 RECEPTOR; KETOCONAZOLE;

ALLERGIC RHINITIS; AREA UNDER THE CURVE; CHRONIC URTICARIA; DOSE RESPONSE; DRUG ACCUMULATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FRUIT JUICE; HEART CONDUCTION; HUMAN; KIDNEY FAILURE; LIVER FAILURE; PRIORITY JOURNAL; QT INTERVAL; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; SIDE EFFECT;

CHOLINERGIC ANTAGONISTS; DRUG MONITORING; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035137186     PISSN: 01081675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. 1 receptors
2. 1 receptor antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergic effects
3. 1 receptor antagonist with antiallergic activity
4. Human mast cell tryptase: A stimulus for microvascular leakage and mast cell activation
5. 4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans
6. Inflammation and the allergic response
7. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors
8. IL-13 and IL-4 are co-expressed in atopic asthma
9. Biology of human TH1 and TH2 cells
10. Bone marrow in atopy and asthma: Hematopoietic mechanisms in allergic inflammation
11. Mast cells as initiators of immunity and host defense
12. RANTES is a chemotactic and activating factor for human eosinophils
13. Chemokines and IL-5: Major players in eosinophil recruitment in asthma
14. Chemokines and allergic disease
15. Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells
16. Adhesion molecules in allergy
17. Inhibition of IgE-mediated and IgE-independent histamine release from human basophil leukocytes in vitro by H1-antagonist, descarbo-ethoxyloratadine
18. Loratadine and desethoxylcarbonylloratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells
19. 2-receptor antagonists
20. 1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines
21. Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells
22. Loratadine reduces RANTES release by an epithelial cell line
23. Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM-1 and HLA-DR by nasal epithelial cells
24. Desloratadine attenuation of eosinophil chemotaxis, adhesion, and superoxide generation
25. Upregulation of tumor necrosis factor α and interleukin-3 expression in lesional and uninvolved skin in different types of urticaria
26. 1 antihistamine
27. 1 receptor antagonist. 2nd communication: Lack of central nervous system and cardiovascular effects
28. Desloratadine has no effect on wakefulness or psychomotor performance
29. Desloratadine does not impair actual driving performance: A 3-way crossover comparison with diphenhydramine and placebo
30. Desloratadine is safe and effective treatment for relief of seasonal allergic rhinitis
31. Desloratadine demonstrates dose proportionality/linear pharmacokinetics in healthy adults
32. Lack of electrocardiographic effects of multiple high doses of desloratadine
33. Race and gender do not affect the multiple dose pharmacokinetics and safety of desloratadine
34. Arrhythmogenic mechanisms of non-sedating antihistamines
35. Torsades de pointes induced by erythromycin and terfenadine
36. Torsades de pointes after treatment with terfenadine and ketoconazole
37. Lack of electrocardiographic effects when desloratadine and ketoconazole are combined
38. Lack of electrocardiographic interaction between desloratadine and erythromycin
39. Grapefruit juice-drug interaction
40. Grapefruit juice reduces the bioavailability of fexofenadine but not desloratadine
41. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
42. Effect of desloratadine on P-glycoprotein (P-gp) transport system (MDR1)
43. The oral bioavailability of desloratadine is unaffected by food
44. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: Possible mechanism for terfenadine-associated cardiotoxicity
45. Cardiac ion channels and antihistamines: Possible mechanisms of cardiotoxicity